Company intelligence / Profile preview

Melius Pharma AB

Lund, Skåne County, Sweden

Ownership: Private
Development stage: Phase 2

Overview

Melius Pharma’s lead candidate, ME‑015 (Suplatast Tosilate), is an oral small molecule with over 25 years of real-world safety data. It is being evaluated in a Phase 2 proof-of-concept study for chronic cough associated with idiopathic pulmonary fibrosis. The compound has shown efficacy and safety benefits across several exploratory studies targeting different types of chronic cough. Topline data from the ongoing Phase 2 trial are expected by early 2025

Therapeutic areas: Pulmonology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

suplatast tosilate

Beyond the preview

Go deeper on Melius Pharma AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melius Pharma AB.

Explore the full profile